Fexofenadine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Rhinitis, Allergic, Perennial

Conditions

Rhinitis, Allergic, Perennial

Trial Timeline

Mar 1, 2002 → —

NCT ID

NCT00741897

About Fexofenadine

Fexofenadine is a approved stage product being developed by Sanofi for Rhinitis, Allergic, Perennial. The current trial status is completed. This product is registered under clinical trial identifier NCT00741897. Target conditions include Rhinitis, Allergic, Perennial.

What happened to similar drugs?

20 of 20 similar drugs in Rhinitis, Allergic, Perennial were approved

Approved (20) Terminated (2) Active (0)

✅placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved

✅ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved

✅BudesonideJohnson & JohnsonApproved

✅Cetirizine + LoratadineJohnson & JohnsonApproved

✅Budesonide + PlaceboAstraZenecaApproved

✅Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved

✅Loratadine + BetamethasoneMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00636870	Approved	Completed	Feb 1, 2003	Jan 1, 2004	Allergic Rhinitis
NCT00638118	Approved	Completed	Feb 1, 2003	May 1, 2003	Allergic Rhinitis
NCT00637585	Approved	Completed	Dec 1, 2002	Jul 1, 2003	Allergic Rhinitis
NCT00741897	Approved	Completed	Mar 1, 2002	—	Rhinitis, Allergic, Perennial
NCT00044811	Phase 3	Completed	Mar 1, 2002	Oct 1, 2003	Asthma
NCT00044824	Phase 3	Completed	Feb 1, 2002	Oct 1, 2003	Asthma

Competing Products

20 competing products in Rhinitis, Allergic, Perennial

See all competitors

Product	Company	Stage	Hype Score
LY3650150 + Placebo + Standard therapy for INCS	Eli Lilly	Phase 3	47
Bilastine + Desloratadine + Placebo	Yuhan	Phase 3	40
ASP4070 + Placebo	Astellas Pharma	Phase 2	35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placebo	Shionogi	Phase 2	35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + Placebo	Ono Pharmaceutical	Phase 2	35
placebo, isotonic ciclesonide, hypotonic ciclesonide	Sumitomo Pharma	Approved	35
ciclesonide nasal aerosol + ciclesonide nasal spray	Sumitomo Pharma	Approved	43
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalation	Sumitomo Pharma	Phase 3	40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	40
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spray	Sumitomo Pharma	Phase 1	29
ciclesonide + mometasone	Sumitomo Pharma	Phase 3	40
DSP-3025 + Placebo	Sumitomo Pharma	Phase 1	29
ciclesonide nasal aerosol + Placebo	Sumitomo Pharma	Phase 3	40
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + Placebo	Sumitomo Pharma	Phase 3	40
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mg	Sumitomo Pharma	Phase 3	40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	40
80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo	Sumitomo Pharma	Phase 3	40
ciclesonide HFA 160 μg	Sumitomo Pharma	Phase 3	40
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo	Sumitomo Pharma	Phase 3	40
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)	Glenmark Pharmaceuticals	Phase 2	35